OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer. Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival. PATIENTS AND METHODS: The study was an open-label, phase II, two-stage design, focusing on the results from the second stage, as criteria for progression were modified after completing the first stage. Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles. Clinical and laboratory assessments were done every 4 weeks, and radiographic scans were obtained every 8 weeks. RESULTS: Twenty-four patients were accrued in the second stage; the median (range) age was 66 (49-85) years, the on-study prostate-specific antigen level was 68.45 (5.8-995) ng/mL, the Gleason score 8 (6-9) and Eastern Cooperative Oncology Group status 1 (in 17 patients). Of the 24 patients, 21 had previous chemotherapy with docetaxel. All patients had bony metastases, either alone (in 11) or with soft-tissue disease (in 13). One patient had a partial response; 10 patients had stable disease (median duration 18 weeks, range 15-48). At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months. For the whole trial of 46 patients the median survival was 18.3 months. Most frequent toxicities included hand-foot skin reaction (grade 2 in nine patients, grade 3 in three), rash, abnormalities in liver function tests, and fatigue. CONCLUSIONS: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.
OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer. Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival. PATIENTS AND METHODS: The study was an open-label, phase II, two-stage design, focusing on the results from the second stage, as criteria for progression were modified after completing the first stage. Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles. Clinical and laboratory assessments were done every 4 weeks, and radiographic scans were obtained every 8 weeks. RESULTS: Twenty-four patients were accrued in the second stage; the median (range) age was 66 (49-85) years, the on-study prostate-specific antigen level was 68.45 (5.8-995) ng/mL, the Gleason score 8 (6-9) and Eastern Cooperative Oncology Group status 1 (in 17 patients). Of the 24 patients, 21 had previous chemotherapy with docetaxel. All patients had bony metastases, either alone (in 11) or with soft-tissue disease (in 13). One patient had a partial response; 10 patients had stable disease (median duration 18 weeks, range 15-48). At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months. For the whole trial of 46 patients the median survival was 18.3 months. Most frequent toxicities included hand-foot skin reaction (grade 2 in nine patients, grade 3 in three), rash, abnormalities in liver function tests, and fatigue. CONCLUSIONS:Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Lillian L Siu; Ahmad Awada; Chris H Takimoto; Martine Piccart; Brian Schwartz; Tom Giannaris; Chetan Lathia; Oana Petrenciuc; Malcolm J Moore Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley Journal: Nat Rev Drug Discov Date: 2006-10 Impact factor: 84.694
Authors: M Moore; H W Hirte; L Siu; A Oza; S J Hotte; O Petrenciuc; F Cihon; C Lathia; B Schwartz Journal: Ann Oncol Date: 2005-07-08 Impact factor: 32.976
Authors: Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz Journal: Oncologist Date: 2007-04
Authors: David F McDermott; Jeffrey A Sosman; Rene Gonzalez; F Stephen Hodi; Gerald P Linette; Jon Richards; James W Jakub; Muralidhar Beeram; Stefano Tarantolo; Sanjiv Agarwala; Gary Frenette; Igor Puzanov; Lee Cranmer; Karl Lewis; John Kirkwood; J Michael White; Chenghua Xia; Kiran Patel; Evan Hersh Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: Sunil Parimi; Misha Eliasziw; Scott North; Marc Trudeau; Eric Winquist; Kim N Chi; Dean Ruether; Tina Cheng; Bernhard J Eigl Journal: Invest New Drugs Date: 2016-08-26 Impact factor: 3.850
Authors: Lokesh Jain; Tristan M Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg Journal: J Exp Clin Cancer Res Date: 2010-07-14